Application of composition in resisting skin aging

Abstract

The invention discloses application of a composition containing ergothioneine, PQQ and NMN / NR. The application comprises the steps of increasing the water content of the skin, improving the skin barrier, resisting saccharification and oxidation, brightening the skin color, whitening the skin and improving the skin elasticity. The composition comprises the following components in parts by weight: 1-100 parts of ergothioneine, 1-100 parts of PQQ or a derivative thereof and 20-1000 parts of a component C, wherein the component C is NMN, NR or a derivative thereof. According to the composition composed of ergothioneine, PQQ and NMN / NR according to a certain proportion, the technical effect of synergistic interaction is achieved, the water content of the skin can be increased, the skin barrier can be improved, the effects of resisting saccharification and oxidation and whitening and brightening the skin color are achieved, the skin elasticity can be improved, and the skin can be tightened.

Description

Technical Field

[0001] The present invention relates to the technical field of anti-aging, and in particular to an application of a composition in anti-skin aging. Background Art

[0002] With rising living standards and a growing pursuit of beauty, demand for anti-aging products in the skincare sector is growing. Skin aging is primarily due to a combination of internal and external factors. From an external perspective, ultraviolet radiation is a key contributor to skin aging. Long-term exposure to ultraviolet radiation produces a large number of free radicals in the skin. These highly oxidizing free radicals attack biomolecules like DNA and proteins in skin cells, disrupting cell structure and function and causing cell damage. This in turn leads to skin aging, wrinkles, hyperpigmentation, and other issues. Furthermore, harmful substances from environmental pollution, such as particulate matter and chemical pollutants, can adhere to the skin's surface and penetrate through the skin, triggering oxidative stress and accelerating the aging process. From an internal perspective, with aging, the body's metabolic rate gradually slows, cell renewal capacity declines, and the function of organelles in skin cells, such as mitochondria, declines, energy synthesis decreases, and cell viability decreases. The synthesis of collagen and elastin fibers in the skin decreases, while their breakdown accelerates, causing the skin to lose elasticity and appear sagging. At the same time, the activity of the body's antioxidant enzyme system decreases, the ability to scavenge free radicals decreases, and free radicals accumulate in the body, further aggravating damage to the skin.

[0003] While numerous anti-aging products exist, they often have limitations. Some contain only a single antioxidant ingredient, resulting in incomplete and inadequate antioxidant effects, unable to effectively combat the effects of multiple free radicals. While some products can replenish collagen, they lack attention to aspects such as cellular energy metabolism and barrier repair, resulting in limited overall skin improvement. Furthermore, the active ingredients in many products are unstable and easily lose activity during production, storage, and use, reducing product efficacy. Summary of the Invention

[0004] The technical problem to be solved by the present invention is to provide an application of a composition comprising ergothioneine, PQQ and NMN / NR in anti-skin aging.

[0005] In order to solve the above technical problems, the present invention provides the following technical solutions:

[0006] A first aspect of the present invention provides a use of a composition in preparing a product for increasing skin moisture content, the composition comprising the following components, by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of pyrroloquinoline quinone (PQQ) or a derivative thereof, and 20 to 1000 parts of component C; wherein component C is nicotinamide mononucleotide (NMN), nicotinamide riboside (NR) or a derivative thereof.

[0007] A second aspect of the present invention provides the use of a composition in preparing a product for improving the skin barrier, the composition comprising the following components by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or its derivatives, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or its derivatives.

[0008] A third aspect of the present invention provides an application of a composition in the preparation of an anti-glycation product, the composition comprising the following components by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

[0009] A fourth aspect of the present invention provides the use of a composition in the preparation of an antioxidant and skin-lightening product, the composition comprising the following components by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or its derivatives, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or its derivatives.

[0010] A fifth aspect of the present invention provides an application of a composition in the preparation of a whitening product, the composition comprising the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

[0011] A sixth aspect of the present invention provides the use of a composition in preparing a product for increasing skin elasticity, the composition comprising the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

[0012] Furthermore, in the above composition, the derivatives of PQQ include salts and crystals of PQQ, preferably pyrroloquinoline quinone disodium salt (PQQ-2Na) or pyrroloquinoline quinone trisodium salt.

[0013] Furthermore, in the above composition, the derivative of NR includes salts, crystals or chlorides of NR.

[0014] Furthermore, in some preferred embodiments, the composition comprises the following components in parts by weight: 10 to 50 parts of ergothioneine, 10 to 30 parts of PQQ, and 100 to 500 parts of NR.

[0015] Further, in some preferred embodiments, the composition comprises the following components in parts by weight: 25 parts of ergothioneine, 20 parts of PQQ, and 300 parts of NR.

[0016] Furthermore, the products include but are not limited to cosmetics, food and medicines.

[0017] Compared with the prior art, the present invention has the following beneficial effects:

[0018] 1. In the present invention, the composition composed of ergothioneine, PQQ and NMN / NR in a certain proportion produces a synergistic technical effect, which can not only increase the skin's moisture content and improve the skin barrier, but also has the effects of anti-glycation, anti-oxidation and whitening and brightening the skin tone, and can also increase skin elasticity and tighten the skin.

[0019] 2. The composition of the present invention can be applied to food, medicine and cosmetics, and can effectively delay skin aging. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The bar graph shows the moisture content of the stratum corneum of the cheek skin of the test product group and the placebo control group;

[0021] Figure 2 The figure is a bar graph of transepidermal water loss of cheek skin in the test product group and the placebo control group;

[0022] Figure 3 The figure is a bar graph showing cheek skin brightness in the test product group and the placebo control group;

[0023] Figure 4 The figure is a bar graph of cheek skin ITA° values for the test product group and the placebo control group;

[0024] Figure 5 The bar graph shows the target spot skin ITA° values for the test product group and the placebo control group;

[0025] Figure 6 The figure is a bar graph of the target spot area of the test product group and the placebo control group;

[0026] Figure 7 The figure is a histogram of cheek skin elasticity in the test product group and the placebo control group;

[0027] Figure 8 The figure is a bar graph of cheek dermis strength in the test product group and the placebo control group;

[0028] Figure 9 The figure is a bar graph showing the number of pores on the cheek skin of the test product group and the placebo control group;

[0029] Figure 10 The figure is a histogram of cheek skin pore volume in the test product group and the placebo control group;

[0030] Figure 11 The figure is a bar graph showing the number of crow's feet in the test product group and the placebo control group;

[0031] Figure 12 The figure is a histogram of crow's feet volume in the test product group and the placebo control group;

[0032] Figure 13 The figure is a bar graph showing the number of nasolabial folds in the test product group and the placebo control group;

[0033] Figure 14 The figure is a bar graph of nasolabial fold volume in the test product group and the placebo control group;

[0034] Figure 15 The figure is a bar graph showing the number of wrinkles at the corners of the mouth in the test product group and the placebo control group;

[0035] Figure 16 The bar graphs show the volume of mouth wrinkles in the test product group and the placebo control group;

[0036] Figure 17 The figure is a bar graph showing cheek skin firmness in the experimental product group and the placebo control group.

[0037] Figure 18 The figure is a bar graph showing the facial jawline contour values of the test product group and the placebo control group. DETAILED DESCRIPTION

[0038] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without making any creative efforts shall fall within the scope of protection of the present invention.

[0039] The present invention will be further described below with reference to specific embodiments and comparative examples.

[0040] The thioneine in the present invention was purchased from Shanghai Thiothioneine Biotechnology Group Co., Ltd. with a purity of ≥99%;

[0041] Pyrroloquinoline quinone disodium salt (PQQ source) was purchased from Fujian Kanghong Biotechnology Co., Ltd. with a purity of ≥99%;

[0042] Nicotinamide riboside chloride (NRCl) was purchased from ChromaDex Group with a purity of ≥95%.

[0043] 1. Examples and Comparative Examples

[0044] This embodiment provides a skin care composition, the formula of which is shown in Table 1. Note: The raw material source of PQQ in the formula below is pyrroloquinoline quinone disodium salt. The PQQ content in the table is the content of pyrroloquinoline quinone disodium salt converted into pyrroloquinoline quinone. The conversion formula is PQQ content = mass of pyrroloquinoline quinone disodium salt / relative molecular weight of pyrroloquinoline quinone disodium salt × relative molecular weight of PQQ.

[0045] Table 1

[0046]

[0047]

[0048] The preparation method of the above composition is as follows: weigh the raw materials according to the formula, mix them evenly, and then obtain the composition.

[0049] 2. Experimental Example: Zebrafish Experiment

[0050] 1. Zebrafish Model

[0051] Zebrafish were kept in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to each liter of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / LCaCO3). The experimental animal use license number is: SYXK (Zhejiang) 2022-0004. The breeding and management of the animals complied with the requirements of the international AAALAC accreditation (certification number: 001458) and the IACUC ethics review number is: IACUC-2024-7045-5-01.

[0052] 2. Detection Method

[0053] 2.1. Hydrating and moisturizing effects

[0054] 4-day-old zebrafish (albino) with a melanin allele mutation were randomly selected and plated in 6-well plates, with 30 treated per well. Samples were administered in water. A positive control group received sodium hyaluronate (15 μg / mL) in water. A normal control group and a model control group were also established, with the volume per well being 3 mL. After 18 hours of treatment at 28°C, all experimental groups except the normal control group received sodium chloride (11 mg / mL) in water to establish a zebrafish water deprivation model. After a further 6 hours of treatment at 28°C, 10 zebrafish were randomly selected from each experimental group and photographed under a dissecting microscope. Images were saved and analyzed using NIS-Elements D 3.20 advanced image processing software. Data were collected and analyzed for zebrafish tail area.

[0055] 2.2. Anti-glycation effect

[0056] 5dpf wild-type AB strain zebrafish were randomly selected and placed in 1.5mL centrifuge tubes, and 10 zebrafish were treated in each tube (experimental group). The samples were given water-soluble, and the positive control group was given aminoguanidine hydrochloride (concentration of 200μg / mL) in water. At the same time, a normal control group and a model control group were set up, and the capacity of each tube was 150μL. Except for the normal control group, the other experimental groups were given 0.4M glucose in water to establish a zebrafish glycation model. Three parallel experiments were set up. After oscillation treatment at 60℃ for 1 day, the supernatant was centrifuged and the data was collected using a multifunctional microplate reader. The AGEs fluorescence value of each experimental group was analyzed, and the anti-glycation efficacy of the sample was evaluated based on the statistical analysis results of this indicator.

[0057] 2.3. Antioxidant Effect

[0058] 6hpf wild-type AB strain zebrafish were randomly selected and plated in a 6-well plate. Thirty zebrafish were treated in each well. Samples were administered with water-soluble hydrogen peroxide, a positive control at a concentration of 2000 μg / mL. A normal control group and a model control group were also set up, with a volume of 3 mL per well. Except for the normal control group, all other groups were administered with water-soluble hydrogen peroxide to establish a zebrafish aging model, with the medium changed daily. Three parallel experiments were performed. After 6 days of treatment at 28°C, zebrafish samples were collected from each experimental group according to the instructions of the SOD assay kit. SOD activity in the zebrafish was detected using a multifunctional microplate reader. The SOD activity of the zebrafish in each experimental group was analyzed, and the anti-aging efficacy of the samples was evaluated based on the statistical analysis results of this indicator.

[0059] After treatment at 28°C for 6 days, zebrafish samples from each experimental group were collected according to the instructions of the GSH determination kit, and the GSH content in the zebrafish was detected using a multifunctional microplate reader. The GSH content of the zebrafish in each experimental group was analyzed, and the anti-aging efficacy of the samples was evaluated based on the statistical analysis results of this indicator.

[0060] 2.4. Whitening effect

[0061] Wild-type AB zebrafish (3 days post-fertilization) were randomly selected and plated in 6-well plates, with 30 zebrafish treated per well. Water-soluble samples were administered, along with a positive control of arbutin at a concentration of 2000 μg / mL. A normal control group and a model control group were also established, with the volume per well being 3 mL. All experimental groups, except the normal control group, were injected with melanocyte-stimulating hormone (MSH) into the yolk sac to establish a zebrafish melanin-enhancing model. After one day of treatment at 28°C, 10 randomly selected zebrafish from each experimental group were photographed under a dissecting microscope. Data were analyzed and collected using ImageJ advanced image processing software. The intensity of melanin signal in the zebrafish heads was analyzed, and statistical analysis of this indicator was used to evaluate the oral whitening efficacy of the samples.

[0062] 2.5. Increase skin elasticity

[0063] Wild-type AB zebrafish (4 dpf) were randomly selected and plated in 6-well plates, with 30 zebrafish treated in each well (experimental group). Water-soluble administration of the samples and a positive control, verisol collagen, were used at a concentration of 250 μg / mL. A normal control group was also established, with a volume of 3 mL per well. Three replicates were performed. After one day of treatment at 28°C, total RNA was extracted from each zebrafish group using the Universal RNA Extraction TL Kit C. Total RNA concentration and purity were determined using a UV-visible spectrophotometer. 2.00 μg of total RNA from the zebrafish samples was synthesized into 20.0 μL of cDNA according to the instructions of the first-strand cDNA synthesis kit. The expression of β-actin, col1a1a, col1a1b, eln1, and eln2 genes was analyzed by q-PCR. β-actin was used as an internal control for gene expression, and the relative RNA expression of col1a1a, col1a1b, eln1, and eln2 genes was calculated.

[0064] 3. Discussion of Results

[0065] 3.1. Hydrating and moisturizing effects

[0066] Table 1 Zebrafish tail area

[0067]

[0068]

[0069] Note: * indicates that compared with the model control group, *p<0.05, ** indicates that compared with the model control group, **p<0.01.

[0070] Please refer to Table 1. Compared with the normal control group, the tail area of zebrafish in the model control group was significantly increased and decreased, and there was a statistical difference between the two, indicating that the zebrafish skin dehydration model was successfully established.

[0071] Compared with model control group, positive controls, embodiment group and comparative example group zebrafish tail area all increase, and this illustrates that the compound of positive controls, embodiment group and comparative example group all has the effect of moisturizing.Wherein in embodiment group, adopt thioneine, PQQ and NR compound to obtain, its zebrafish tail area is significantly higher than comparative example group, and with significant difference between model control group.This illustrates that there is significant synergistic effect between each component in the formula of embodiment group, can play significant moisturizing effect.

[0072] 3.2. Anti-glycation effect

[0073] Table 2 AEGs levels in zebrafish

[0074]

[0075]

[0076] Note: * indicates that compared with the model control group, *p<0.05; ** indicates that compared with the model control group, **p<0.01.

[0077] Please refer to Table 2. Compared with the normal control group, the AEGs level in the zebrafish in the model control group was significantly increased, and there was a statistical difference between the two, indicating that the zebrafish AGEs increase model was successfully established.

[0078] Compared with model control group, AEGs levels in positive controls, embodiment group and comparative example group zebrafish are all reduced, which illustrates that the compound of positive controls, embodiment group and comparative example group has anti-glycosylation effect.Wherein the compound obtained by using thioneine, PQQ and NR to be compounded in embodiment group, the reduction amplitude of its AEGs levels is significantly higher than comparative example group, and with significant difference between model control group.This illustrates that there is significant synergistic effect between each component in the formula of embodiment group, can play significant anti-glycosylation effect.

[0079] 3.3. Antioxidant effect

[0080] Table 3 SOD activity in zebrafish

[0081]

[0082]

[0083] Note: * indicates that compared with the model control group, *p<0.05; ** indicates that compared with the model control group, **p<0.01.

[0084] Please refer to Table 3. Compared with the normal control group, the SOD activity level of zebrafish in the model control group was significantly reduced, and there was a statistical difference between the two, indicating that the zebrafish antioxidant model was successfully established.

[0085] Compared with model control group, SOD activity level in positive controls, embodiment group and comparative example group zebrafish increases, and this illustrates that the compound of positive controls, embodiment group and comparative example group has anti-oxidative effect.Wherein the compound obtained using thioneine, PQQ and NR composite in embodiment group, the amplitude that its SOD activity level increases is significantly higher than comparative example group, and with there is significant difference between model control group.This illustrates that there is significant synergistic effect between each component in the formula of embodiment group, can play significant anti-oxidative effect.

[0086] Table 4 GSH content in zebrafish

[0087]

[0088]

[0089] Note: * indicates that compared with the model control group, *p<0.05; ** indicates that compared with the model control group, **p<0.01.

[0090] Please refer to Table 4. Compared with the normal control group, the GSH content level in the zebrafish of the model control group was significantly reduced, and there was a statistical difference between the two, indicating that the zebrafish antioxidant model was successfully established.

[0091] Compared with model control group, GSH content level in positive controls, embodiment group and comparative example group zebrafish increases, and this illustrates that the compound of positive controls, embodiment group and comparative example group has anti-oxidative effect.Wherein in embodiment group, adopt thioneine, PQQ and NR to compound and obtain, the amplitude that its GSH content level increases is significantly higher than comparative example group, and with there is significant difference between model control group.This illustrates that there is significant synergistic effect between each component in the formula of embodiment group, can play significant anti-oxidative effect.

[0092] 3.4. Whitening effect

[0093] Table 5 Melanin signal intensity in zebrafish head

[0094] Concentration (μg / mL) Melanin signal intensity in zebrafish head (px) Normal control group / <![CDATA[137213±3842 ** ]]> Model control group / 202164±1834 Positive control group 2000 <![CDATA[134944±2021 ** ]]> Example 1 250 <![CDATA[139614±3112 ** ]]> Example 2 250 <![CDATA[139129±2836 ** <!-- 8 -->]]> Example 3 250 <![CDATA[140241±1394 ** ]]> Example 4 250 <![CDATA[138603±2117 ** ]]> Comparative Example 1 250 <![CDATA[179643±1130 * ]]> Comparative Example 2 250 <![CDATA[179542±1839 * ]]> Comparative Example 3 250 <![CDATA[173214±2193 * ]]> Comparative Example 4 250 <![CDATA[166603±1829 * ]]> Comparative Example 5 250 <![CDATA[169678±2047 * ]]> Comparative Example 6 250 <![CDATA[166219±1038 * ]]>

[0095] Note: * indicates that compared with the model control group, *p<0.05; ** indicates that compared with the model control group, **p<0.01.

[0096] Please see Table 5. Compared with the normal control group, the melanin signal intensity of the zebrafish in the model control group was significantly increased, and there was a significant difference between the two, indicating that the zebrafish melanin increase model was successfully established.

[0097] Compared with model control group, positive controls, embodiment group and comparative example group zebrafish head melanin signal intensity are all reduced, and this illustrates that the compound of positive controls, embodiment group and comparative example group all has whitening effect.Wherein in embodiment group, adopt thioneine, PQQ and NR compound to obtain, the amplitude that zebrafish head melanin signal intensity reduces is significantly higher than comparative example group, and with there is significant difference between model control group.This illustrates that there is synergistic effect between each component in the formula of embodiment group, can play significant whitening effect.

[0098] 3.5. Increase skin elasticity

[0099] Table 6 Zebrafish gene expression levels

[0100]

[0101] Note: * indicates that compared with the normal control group, *p<0.05; ** indicates that compared with the normal control group, **p<0.01.

[0102] Refer to Table 6, compared with the normal control group, the positive control group, embodiment group and comparative example group zebrafish skin type I collagen (col1a1a, col1a1b) and elastin (eln1, eln2) gene relative expression amounts are all increased, which illustrates that the compound of the positive control group, embodiment group and comparative example group all has the effect of increasing skin elasticity.Wherein the embodiment group adopts thioneine, PQQ and NR compound to obtain compound, the amplitude that zebrafish skin type I collagen (col1a1a, col1a1b) and elastin (eln1, eln2) gene relative expression amount increases is significantly higher than comparative example group, and with significant difference between the normal control group.This illustrates that the effect of synergistic enhancement is produced between each component in the formula of embodiment group, can play the effect of significantly increasing skin elasticity.

[0103] 3. Experimental Example: Human Skin Experiment

[0104] 1. Experimental Design

[0105] Sixty-six healthy female subjects aged 35 to 60 were selected and divided into two groups (a test product group and a placebo control group). Participants were required to have facial skin that lacks elasticity, has sagging skin, and a dull complexion; visible nasolabial folds and wrinkles around the mouth, visible crow's feet around the eyes; large pores on the cheeks, and pigmentation in the cheek area. Furthermore, they had not used any products with the same efficacy as the test product, such as those for freckle removal, whitening, repairing, firming, or anti-wrinkle, in the month prior to the trial.

[0106] Subjects in the test product group orally took the composition of Example 1, while subjects in the placebo control group orally took a placebo. One tablet was taken daily for 56 consecutive days. The facial skin condition of the subjects was measured using an instrument at specific time points. The specific test items and methods are shown in Table 7.

[0107] Table 7

[0108]

[0109]

[0110] 2. Results and Analysis

[0111] 2.1. Hydrating and moisturizing

[0112] See Figure 1-2 After taking the placebo control group for 14 days, 28 days and 56 days, the water content of the cheek skin stratum corneum and the transepidermal water loss rate of the cheek skin did not change much compared with before taking the placebo control group.

[0113] After 14 days of use, the test product group saw a 43.31% increase in cheek stratum corneum water content and a 13.78% decrease in transepidermal water loss. After 28 days, the stratum corneum water content increased by 52.2% and the transepidermal water loss decreased by 18.99%. After 56 days, the stratum corneum water content increased by 64.34% and the transepidermal water loss decreased by 21.51%. Furthermore, after 14, 28, and 56 days of use, the stratum corneum water content and transepidermal water loss in the test product group were significantly different from pre-use levels, and also significantly different from the placebo control group.

[0114] It can be seen from this that the composition of Example 1 of the present invention helps to improve the moisture content of facial skin, improve the barrier function of facial skin, and reduce water loss.

[0115] 2.2. Whitening, brightening and spot removal

[0116] See Figure 3-6 After taking the placebo group for 14 days, 28 days and 56 days, the cheek skin brightness was L *The ITA° values of cheek skin and target spot skin did not change much compared with before taking the medicine, while the area of target spot increased.

[0117] After taking the test product for 14 days, the cheek skin brightness was L * The value of cheek skin ITA° increased by 0.74%, the ITA° value of target spot skin increased by 3.76%, the ITA° value of target spot skin increased by 2.01%, and the area of target spot decreased by 7.42%; after taking it for 28 days, the brightness of cheek skin L * The value of cheek skin ITA° increased by 0.94%, the ITA° value of target spot skin increased by 4.77%, the ITA° value of target spot skin increased by 3.65%, and the area of target spot decreased by 8.32%. After taking it for 56 days, the brightness of cheek skin L * The value of the skin brightness increased by 1.05%, the ITA value of the cheek skin increased by 6.19%, the ITA value of the target spot skin increased by 5.03%, and the target spot area decreased by 10.74%. In addition, after taking the test product for 14 days, 28 days and 56 days, the cheek skin brightness L * The values of cheek skin ITA°, target spot skin ITA° and target spot area were significantly different compared with those before taking the drug, and were also significantly different from those of the placebo control group.

[0118] It can be seen from this that the composition of Example 1 of the present invention helps whiten the skin, improve skin brightness, and lighten skin spots.

[0119] 2.3. Improve skin elasticity

[0120] See Figure 7-8 After taking the placebo control group for 14 days, 28 days and 56 days, the cheek skin elasticity and cheek dermis strength did not change much compared with before taking the placebo control group.

[0121] After 14 days of treatment, the test product group experienced a 5.19% increase in cheek skin elasticity and a 15.90% increase in cheek dermis strength. After 28 days, cheek skin elasticity increased by 10.81% and cheek dermis strength by 22.33%. After 56 days, cheek skin elasticity increased by 15.62% and cheek dermis strength by 24.24%. Furthermore, after 14, 28, and 56 days of treatment, cheek skin elasticity and cheek dermis strength in the test product group showed significant differences compared to pre-treatment levels, as well as significant differences compared to the placebo control group.

[0122] It can be seen from this that the composition of Example 1 of the present invention helps to improve facial skin elasticity, increase skin collagen content, and improve skin plumpness.

[0123] 2.4. Skin firming

[0124] See Figure 9-18After taking the placebo control group for 14 days, 28 days and 56 days, the number of cheek skin pores, cheek skin pore volume, number of crow's feet, crow's feet volume, number of nasolabial folds, nasolabial fold volume, number of corner mouth wrinkles, length of corner mouth wrinkles, cheek skin firmness and facial jawline contour values had little change compared with before taking the medicine.

[0125] See Figure 9-10 After 14 days of use, the number of cheek pores decreased by 6.35% and the volume of cheek pores decreased by 7.65% in the test product group. After 28 days of use, the number of cheek pores decreased by 8.38% and the volume of cheek pores decreased by 8.29%. After 56 days of use, the number of cheek pores decreased by 12.02% and the volume of cheek pores decreased by 13.47%. In addition, after 14, 28, and 56 days of use, the number of cheek pores and the volume of cheek pores in the test product group showed significant differences compared to pre-use, and also showed significant differences compared to the placebo control group.

[0126] See Figure 11-12 After 14 days of treatment, the number of crow's feet in the test product group decreased by 29.19% and the volume of crow's feet decreased by 6.04%. After 28 days of treatment, the number of crow's feet decreased by 30.67% and the volume of crow's feet decreased by 7.12%. After 56 days of treatment, the number of crow's feet decreased by 31.59% and the volume of crow's feet decreased by 13.75%. In addition, after 14, 28, and 56 days of treatment, the number and volume of crow's feet in the test product group showed significant differences compared to pre-treatment, and also showed significant differences compared to the placebo control group.

[0127] See Figure 13-14 After 14 days of treatment, the number of nasolabial folds in the test product group decreased by 20.77% and their volume decreased by 4.93%. After 28 days of treatment, the number of nasolabial folds decreased by 22.67% and their volume decreased by 5.49%. After 56 days of treatment, the number of nasolabial folds decreased by 24.56% and their volume decreased by 6.33%. Furthermore, after 14, 28, and 56 days of treatment, the number and volume of nasolabial folds in the test product group showed significant differences compared to pre-treatment levels, as well as significant differences compared to the placebo control group.

[0128] See Figure 15-16After 14 days of use, the number of wrinkles at the corners of the mouth decreased by 13.1% and their length decreased by 11.29%. After 28 days of use, the number of wrinkles at the corners of the mouth decreased by 17.86% and their length decreased by 16.03%. After 56 days of use, the number of wrinkles at the corners of the mouth decreased by 21.03% and their length decreased by 25.36%. Furthermore, after 14, 28, and 56 days of use, the number and length of wrinkles at the corners of the mouth in the test product group were significantly different from those before use, and also significantly different from those in the placebo control group.

[0129] See Figure 17-18 After 14 days of use, the test product group experienced a 5.16% increase in cheek skin firmness and a 0.34% increase in jawline contour. After 28 days, cheek skin firmness increased by 9.52% and jawline contour by 0.53%. After 56 days, cheek skin firmness increased by 11.52% and jawline contour by 0.83%. Furthermore, after 14, 28, and 56 days of use, cheek skin firmness and jawline contour in the test product group showed significant differences compared to pre-use, as well as significant differences compared to the placebo control group.

[0130] It can be seen that the composition of Example 1 of the present invention helps to improve skin pores, reduce crow's feet, nasolabial folds and wrinkles at the corners of the mouth, lift the jawline of the face, and increase the firmness of the cheek skin.

[0131] In summary, the composition comprising ergothioneine, PQQ and NMN / NR provided by the present invention produces a synergistic technical effect in anti-skin aging, which can not only increase skin moisture content and improve skin barrier, but also has the effects of whitening, brightening skin tone, and fading spots, and can also increase skin elasticity and tighten the skin.

[0132] The above embodiments are merely preferred embodiments for the purpose of fully illustrating the present invention, and the scope of protection of the present invention is not limited thereto. Equivalent substitutions or modifications made by those skilled in the art based on the present invention are within the scope of protection of the present invention. The scope of protection of the present invention shall be subject to the claims.

Claims

1. Use of the composition in preparing a product for increasing skin moisture content, characterized in that: The composition comprises the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

2. Use of the composition in preparing a product for improving skin barrier, characterized in that: The composition comprises the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

3. The use of the composition in the preparation of anti-glycation products, characterized in that: The composition comprises the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

4. Use of the composition in preparing products for anti-oxidation and skin-lightening, characterized in that: The composition comprises the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

5. Use of the composition in preparing whitening products, characterized in that, The composition comprises the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

6. Use of the composition in preparing a product for increasing skin elasticity, characterized in that: The composition comprises the following components in parts by weight: 1 to 100 parts of ergothioneine, 1 to 100 parts of PQQ or a derivative thereof, and 20 to 1000 parts of component C; wherein the component C is NMN, NR or a derivative thereof.

7. The use according to any one of claims 1 to 6, characterized in that The composition comprises the following components in parts by weight: 10 to 50 parts of ergothioneine, 10 to 30 parts of PQQ, and 100 to 500 parts of NR.

8. The use according to any one of claims 1 to 6, characterized in that: The composition comprises the following components in parts by weight: 25 parts of ergothioneine, 20 parts of PQQ, and 300 parts of NR.

9. The use according to any one of claims 1 to 6, characterized in that: The products include cosmetics, food and medicines.

Images